At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
300 mg [C14] CT1812drug
Likely dose
300 mg [C14] CT1812from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C] CT1812 in Healthy Adult Male Subjects
In Brief
A Phase 1 clinical trial evaluating 300 mg [C14] CT1812 for Alzheimer Disease. Completed, enrolled 8 participants across 1 site.
Detailed Summary
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartDec 2021
Primary CompletionJan 2022
Study CompletionJan 2022
First PostedFeb 2022
TodayJul 2026
First PostedFeb 4, 2022
Enrollment StartDec 31, 2021
Primary CompletionJan 17, 2022
Study CompletionJan 24, 2022
TodayJul 2, 2026
Enrollment to primary: 16 daysPosted 4.4 years ago
Interventions
300 mg [C14] CT1812drug
Single dose of 300 mg CT1812 with microtracer dose of \[C14\]